Noveris Health Sciences Inc.
Noveris Health Sciences Inc.
Your view on MYCOF
Overview
What the company does, where it operates, and who runs it.
About Noveris Health Sciences Inc.
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- David Joshua Bartch
- Headquarters
- 789 West Pender Street, Vancouver, BC, CA
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- David Joshua Bartch
- Headquarters
- 789 West Pender Street, Vancouver, BC, CA
Noveris Health Sciences Inc. is a biotechnology company, which engages in the research, drug development, and clinical trials of psilocybin products. The company was founded by Parente Carman, Damon Michaels, and Robert Roscow on September 27, 2013 and is headquartered in Vancouver, Canada.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Noveris Health Sciences Inc., and the rating behind it. MYCOF last traded at $0.13; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Noveris Health Sciences Inc.. Starting points for Noveris Health Sciences Inc.: EPS -$0.0050, beta 2.34 — an Medical - Pharmaceuticals name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Noveris Health Sciences Inc.. Noveris Health Sciences Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Noveris Health Sciences Inc.. Trailing twelve-month EPS for Noveris Health Sciences Inc. stands at -$0.0050. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Noveris Health Sciences Inc.. Noveris Health Sciences Inc. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Noveris Health Sciences Inc. valued side by side against its closest peers. Noveris Health Sciences Inc. is measured against Medical - Pharmaceuticals peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Noveris Health Sciences Inc., and how their positions are changing. At a $8.1M market value, institutional positions materially move Noveris Health Sciences Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Noveris Health Sciences Inc. executives and directors. Shares of Noveris Health Sciences Inc. have traded between $0.03 and $0.45 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Noveris Health Sciences Inc.. Noveris Health Sciences Inc. is a $8.1M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Noveris Health Sciences Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Noveris Health Sciences Inc.. Coverage tracks Noveris Health Sciences Inc. within Medical - Pharmaceuticals (Healthcare). Press releases and market coverage, newest first.